Motif Bio Plc – Invitation to Present at Infectious Diseases Conference

22 June 2017

Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr. David Huang, Chief Medical Officer at Motif Bio, has been invited to present a clinical development overview of iclaprim during the formal Symposia session at IDWeek 2017 on October 5, 2017. In addition, Dr. Huang will lead a “Meet-the-Professors Session” in a clinically oriented Q&A session on October 6, 2017.


IDWeek is the combined annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, HIV Medicine Association and Pediatric Infectious Diseases Society. The Symposia session is focused on clinical programmes in late clinical development and closest to regulatory approval.


Commenting on the invitation David Huang, CMO at Motif Bio said: “IDWeek is a major event for infectious disease professionals and I am delighted that the IDWeek Committee have selected iclaprim for presentation.  I look forward to presenting the positive data from the REVIVE-1 trial.  We believe these data suggest iclaprim may serve as an important differentiated antibiotic option in an era of emerging antibiotic resistant infections.”


For further information please contact:

Motif Bio plc

Graham Lumsden (Chief Executive Officer)

David Huang (Chief Medical Officer)


Walbrook PR Ltd. (FINANCIAL PR & IR)

Paul McManus

Mike Wort

+44 (0)20 7933 8780 or

Mob: +44 (0)7980 541 893

Mob: +44 (0)7900 608 002

Raimund Gabriel +49 (0)89 210 2280


Notes to Editors

 About iclaprim

Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics. Iclaprim exhibits potent activity against Gram-positive clinical isolates of many genera of staphylococci, including methicillin-sensitive staphylococci (MSSA) and methicillin-resistant staphylococci (MRSA). The MIC90 of iclaprim was lower, demonstrating higher potency, than most comparators including vancomycin and linezolid, standard of care therapies used in serious and life-threatening Gram-positive hospital infections. To date, iclaprim has been studied in over 1,000 patients and healthy volunteers. No dosage adjustment is required in patients with renal impairment, or in obese patients. The iclaprim fixed dose may help reduce the resources required in hospitals since dosage adjustment by health care professionals is avoided, and overall hospital treatment costs may be lower, especially in renally impaired patients

About Motif Bio


Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin-resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.




Is attended by over 6000 healthcare professionals practicing or involved in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists.  In addition, public health officials, including those who see HIV and pediatric patients attend in numbers.  It is a meeting for professionals who want to stay current and apply state-of-the art science to clinical care, and excel in their own career.

This information is provided by RNS

The company news service from the London Stock Exchange